The use of niraparib in the treatment of ovarian cancer

Abstract

This case report describes the case of a patient with ovarian cancer who, in addition to surgery and chemotherapy, also received targeted treatment - PARP (poly(ADP-ribose) polymerase) inhibitor niraparib. A satisfactory stabilization of recurrent disease was achieved as a result of such treatment.

However, adequately performed surgical procedure remains crucial in the treatment of ovarian cancer.

Keywords

• ovarian cancer
• PARP inhibitor
• niraparib